Physician profile
Ari Baron
NPI 1013086420
$704,794.13
in general payments reported to CMS, 2019-2025
81 companies · $82K in 2025
The $82K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $194K · 2020: $54K · 2021: $102K · 2022: $114K · 2023: $109K · 2024: $49K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $195K · Consulting Fee: $32K · Food and Beverage: $10K · Travel and Lodging: $2,731 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $750 · Education: $48.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $194,632.00 |
| Consulting Fee | $32,087.00 |
| Food and Beverage | $10,034.85 |
| Travel and Lodging | $2,730.56 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $750.00 |
| Education | $48.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $305,707.78 | 2019-2025 | Opdivo, Camzyos, Reblozyl |
| Lilly USA, LLC | $105,291.33 | 2019-2024 | Retevmo, Jaypirca, Verzenio |
| Abbvie INC. | $57,591.61 | 2019-2025 | Venclexta, Creon |
| Bayer Healthcare Pharmaceuticals INC. | $51,630.17 | 2020-2025 | |
| Exelixis INC. | $39,113.97 | 2019-2025 | Cabometyx |
| Janssen Biotech, INC. | $32,610.51 | 2019-2024 | Rybrevant, Tecvayli |
| Astellas Pharma US INC | $23,995.24 | 2019-2025 | Vyloy, Padcev, Xospata |
| Eisai INC. | $22,913.75 | 2019-2024 | |
| Amgen INC. | $21,487.96 | 2019-2025 | Vectibix, Vectibix, Imdelltra (Amg757) |
| Taiho Oncology, INC. | $10,912.48 | 2019-2025 | |
| Incyte Corporation | $7,140.87 | 2019-2025 | Zynyz, Monjuvi, Jakafi |
| Pfizer INC. | $7,049.00 | 2019-2025 | |
| Celgene Corporation | $2,385.57 | 2019-2025 | Reblozyl, Opdivo, Pomalyst |
| G1 Therapeutics, INC. | $2,269.28 | 2022-2023 | Cosela |
| Genentech USA, INC. | $2,107.73 | 2019-2025 | Lunsumio, Phesgo, Polivy |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $1,950.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,898.92 | 2019-2025 | Enhertu, Tagrisso, Imfinzi |
| Astrazeneca Uk Limited | $1,370.00 | 2020 | |
| Deciphera Pharmaceuticals INC. | $899.40 | 2020-2025 | Qinlock, Romvimza |
| Merck Sharp & Dohme LLC | $493.25 | 2019-2025 | Keytruda, Welireg, Lenvima |
| Pharmacyclics LLC, An Abbvie Company | $451.62 | 2019-2023 | Imbruvica, Epkinly |
| Novartis Pharmaceuticals Corporation | $406.74 | 2019-2025 | |
| Octapharma USA, INC. | $351.56 | 2020-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Glaxosmithkline, LLC. | $350.88 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $306.06 | 2020-2025 | Fruzaqla, Alunbrig, Iclusig |
| Gilead Sciences, INC. | $262.97 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $224.88 | 2019-2024 | |
| Seagen INC. | $204.06 | 2019-2023 | Adcetris |
| Servier Pharmaceuticals LLC | $201.77 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $184.43 | 2020-2024 | Ultomiris |
| Blueprint Medicines Corporation | $184.37 | 2020-2025 | Ayvakit |
| Daiichi Sankyo INC. | $157.57 | 2019-2025 | Enhertu, Vanflyta |
| Rigel Pharmaceuticals, INC. | $152.72 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Adc Therapeutics America, INC. | $150.67 | 2022-2025 | |
| Coherus Oncology, INC. | $146.76 | 2021-2025 | Loqtorzi |
| Jazz Pharmaceuticals INC. | $133.79 | 2020-2025 | Zepzelca |
| Karyopharm Therapeutics INC. | $117.93 | 2020-2025 | Xpovio |
| Pharmaessentia USA Corporation | $116.84 | 2023-2025 | Besremi |
| Regeneron Healthcare Solutions, INC. | $109.99 | 2022-2024 | Libtayo |
| Puma Biotechnology, INC. | $101.36 | 2019-2024 | |
| Sobi, INC | $97.96 | 2022-2025 | |
| Acrotech Biopharma INC. | $81.12 | 2021-2024 | Beleodaq |
| Aveo Pharmaceuticals, INC. | $80.06 | 2022-2025 | Fotivda |
| Pharmacosmos Therapeutics INC. | $79.65 | 2021-2024 | Cosela |
| Secura Bio, INC. | $76.64 | 2022-2025 | Copiktra |
| Springworks Therapeutics, INC. | $76.08 | 2024-2025 | Ogsiveo |
| Clovis Oncology, INC. | $73.16 | 2019-2022 | |
| Kyowa Kirin, INC. | $63.50 | 2022-2025 | Poteligeo |
| Beigene USA, INC. | $61.71 | 2022-2025 | Tevimbra |
| Emd Serono, INC. | $58.64 | 2019-2021 | |
| Syndax Pharmaceuticals, INC. | $57.49 | 2025 | Revuforj |
| Ipsen Biopharmaceuticals, INC | $56.58 | 2022-2025 | Onivyde |
| Kite Pharma, INC. | $46.49 | 2021-2022 | |
| Mirati Therapeutics, INC. | $45.54 | 2023-2024 | Krazati |
| Heron Therapeutics, INC. | $45.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.02 | 2019-2021 | |
| Epizyme, INC. | $42.53 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $42.25 | 2023-2024 | Empaveli |
| Dova Pharmaceuticals | $40.11 | 2020-2021 | |
| Myriad Genetic Laboratories, INC. | $39.56 | 2023-2024 | Precisetumor |
| Spectrum Pharmaceuticals INC. | $39.32 | 2019-2025 | Rolvedon |
| Genentech, INC. | $38.76 | 2022 | |
| Array Biopharma INC | $38.41 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $37.87 | 2020-2021 | |
| Geron Corporation | $35.95 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $34.66 | 2025 | Orserdu |
| Legend Biotech USA INC. | $27.88 | 2025 | Carvykti |
| Cti Biopharma Corp. | $25.30 | 2023 | Vonjo |
| Morphosys, US INC. | $23.49 | 2023 | Monjuvi |
| Allergan, INC. | $22.50 | 2020 | |
| Agios Pharmaceuticals, INC. | $21.13 | 2019 | |
| Mylan Institutional INC. | $19.90 | 2020 | |
| Tesaro, INC. | $19.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.18 | 2019 | |
| Sirtex Medical INC | $17.12 | 2019 | |
| Aurobindo Pharma USA, INC. | $14.72 | 2020 | |
| Verastem, INC. | $14.18 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$236.62 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Baron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.